Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Werte in diesem Artikel
DUBLIN, Jan. 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 15, 2025 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content:https://www.prnewswire.co.uk/news-releases/alkermes-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302341500.html
Ausgewählte Hebelprodukte auf Alkermes
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Alkermes
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Alkermes PLC
Analysen zu Alkermes PLC
Datum | Rating | Analyst | |
---|---|---|---|
31.05.2019 | Alkermes Neutral | H.C. Wainwright & Co. | |
14.12.2018 | Alkermes Underperform | Wolfe Research | |
07.08.2018 | Alkermes Hold | Stifel, Nicolaus & Co., Inc. | |
06.06.2018 | Alkermes Buy | B. Riley FBR, Inc. | |
16.10.2017 | Alkermes Equal Weight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
07.08.2018 | Alkermes Hold | Stifel, Nicolaus & Co., Inc. | |
06.06.2018 | Alkermes Buy | B. Riley FBR, Inc. | |
07.10.2015 | Alkermes Overweight | Barclays Capital | |
21.05.2015 | Alkermes Overweight | Barclays Capital | |
08.01.2015 | Alkermes Buy | Mizuho |
Datum | Rating | Analyst | |
---|---|---|---|
31.05.2019 | Alkermes Neutral | H.C. Wainwright & Co. | |
16.10.2017 | Alkermes Equal Weight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2018 | Alkermes Underperform | Wolfe Research |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Alkermes PLC nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen